Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

ALX-0600

Known as: ALX 0600 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
BACKGROUND Malabsorption of nutrients, fluids and electrolytes is a key finding in patients with short bowel syndrome. If not… Expand
Review
2006
Review
2006
Objective: To summarize the pharmacology, development, and clinical application of teduglutide (ALX-0600), a glucagon-like… Expand
Highly Cited
2005
Highly Cited
2005
Background and aims: Glucagon-like peptide 2 (GLP-2) may improve intestinal absorption in short bowel syndrome (SBS) patients… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
2001
2001
NPS Allelix (formerly Allelix Biopharmaceuticals) is developing the glucagon-like peptide 2 (GLP-2) analog ALX-0600 for the… Expand
Review
2001
Review
2001
  • D. Sigalet
  • Current opinion in investigational drugs
  • 2001
  • Corpus ID: 27423675
NPS Allelix (formerly Allelix Biopharmaceuticals) is developing the glucagon-like peptide 2 (GLP-2) analog ALX-0600 for the… Expand
Highly Cited
2001
Highly Cited
2001
BACKGROUND Acute pancreatitis (AP) initiates a generalized inflammatory response that increases intestinal permeability and… Expand
Highly Cited
2000
Highly Cited
2000
BACKGROUND Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been… Expand
Highly Cited
2000
Highly Cited
2000
PURPOSE Treatment of short bowel syndrome (SBS) can be difficult; this study examines the effect of parental administration of… Expand